



Clinical trial results:

Open, multi-centric, post-marketing surveillance (PMS) to evaluate the reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, Rotarix when administered according to a 0, 2 month schedule to Sri Lankan infants aged at least 6 weeks at the time of first vaccination.

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2015-001546-28 |
| Trial protocol | Outside EU/EEA |
| Global end of trial date | 26 August 2009 |

Results information

| | |
|--------------------------------|---|
| Result version number | v2 (current) |
| This version publication date | 11 August 2022 |
| First version publication date | 10 July 2015 |
| Version creation reason | <ul style="list-style-type: none">• Correction of full data set Correction of full data set and alignment between registries. |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | 111664 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT00779779 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | GlaxoSmithKline Biologicals |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium, B-1330 |
| Public contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com |
| Scientific contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com |

Notes:

Paediatric regulatory details

| | |
|--|-----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

Results analysis stage

| | |
|--|-----------------|
| Analysis stage | Final |
| Date of interim/final analysis | 13 January 2010 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 25 May 2009 |
| Global end of trial reached? | Yes |
| Global end of trial date | 26 August 2009 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To assess the reactogenicity of Rotarix in terms of occurrence of at least one grade "2" or grade "3" fever, vomiting or diarrhoea within a 8-day follow-up period after each vaccine dose.

Protection of trial subjects:

The subjects were observed closely for at least 30 minutes following the administration of vaccines, with appropriate medical treatment readily available in case of a rare anaphylactic reaction.

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 22 November 2008 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|----------------|
| Country: Number of subjects enrolled | Sri Lanka: 522 |
| Worldwide total number of subjects | 522 |
| EEA total number of subjects | 0 |

Notes:

Subjects enrolled per age group

| | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 522 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

Period 1

| | |
|------------------------------|---------------------------------|
| Period 1 title | Overall period (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Arms

| | |
|-----------|---------------|
| Arm title | Rotarix Group |
|-----------|---------------|

Arm description:

Subjects received 2 oral doses of Rotarix vaccine at an interval of at least 4 weeks between doses. The first dose was given from the age of 6 weeks and vaccination with both doses was to be completed by 24 weeks of age.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | Rotarix |
| Investigational medicinal product code | |
| Other name | HRV |
| Pharmaceutical forms | Powder and solvent for oral suspension |
| Routes of administration | Oral use |

Dosage and administration details:

Two oral doses, with at least 4 weeks interval in-between.

| Number of subjects in period 1 | Rotarix Group |
|--------------------------------|---------------|
| Started | 522 |
| Completed | 498 |
| Not completed | 24 |
| Consent withdrawn by subject | 4 |
| Adverse event, non-fatal | 1 |
| Protocol Violation | 14 |
| Lost to follow-up | 5 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|---------------|
| Reporting group title | Rotarix Group |
|-----------------------|---------------|

Reporting group description:

Subjects received 2 oral doses of Rotarix vaccine at an interval of at least 4 weeks between doses. The first dose was given from the age of 6 weeks and vaccination with both doses was to be completed by 24 weeks of age.

| Reporting group values | Rotarix Group | Total | |
|---|---------------|-------|--|
| Number of subjects | 522 | 522 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 522 | 522 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 0 | 0 | |
| From 65-84 years | 0 | 0 | |
| 85 years and over | 0 | 0 | |
| Age continuous | | | |
| Units: weeks | | | |
| arithmetic mean | 12.5 | | |
| standard deviation | ± 5.62 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 267 | 267 | |
| Male | 255 | 255 | |

End points

End points reporting groups

| | |
|--|---------------|
| Reporting group title | Rotarix Group |
| Reporting group description: Subjects received 2 oral doses of Rotarix vaccine at an interval of at least 4 weeks between doses. The first dose was given from the age of 6 weeks and vaccination with both doses was to be completed by 24 weeks of age. | |

Primary: Number of subjects with at least one \geq Grade "2" fever, vomiting or diarrhoea

| | |
|--|---|
| End point title | Number of subjects with at least one \geq Grade "2" fever, vomiting or diarrhoea ^[1] |
| End point description: Grade 2 fever was defined as axillary temperature > 38.0 to ≤ 39.0 degrees Celsius and grade 3 fever as axillary temperature > 39.0 degrees Celsius. Grade 2 vomiting was defined as 2 episodes of vomiting per day and grade 3 as 3 or more episodes of vomiting per day. Grade 2 diarrhoea was defined as 4-5 looser than normal stools per day and grade 3 as 6 or more looser than normal stools a day. | |
| End point type | Primary |
| End point timeframe: During the 8-day solicited follow-up period after each vaccine dose (Dose 1 and Dose 2) | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Rotarix Group | | | |
|--|-----------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 522 | | | |
| Units: Subjects | | | | |
| Grade 2/3 fever, vomiting or diarrhoea; Dose 1 | 46 | | | |
| Grade 2/3 fever, vomiting or diarrhoea; Dose 2 | 50 | | | |
| Grade 2/3 fever, vomiting or diarrhoea; Across doses | 78 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting each type of solicited general symptoms

| | |
|--|--|
| End point title | Number of subjects reporting each type of solicited general symptoms |
| End point description: Assessed solicited general symptoms were cough, diarrhoea, irritability, loss of appetite, fever (degrees Celsius) and vomiting. Any = occurrence of the symptom regardless of intensity and relationship to vaccination. Grade 3 Cough and Irritability = symptoms which prevented normal everyday activities. Grade 3 Diarrhoea = 6 looser than normal stools/day. Grade 3 Loss of appetite = Not eating at all. | |

| | |
|---|-----------|
| End point type | Secondary |
| End point timeframe: | |
| During the 8-day follow-up period after each vaccine dose (Dose 1 and Dose 2) | |

| End point values | Rotarix Group | | | |
|--|-----------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 522 | | | |
| Units: Subjects | | | | |
| Any Cough; Dose 1 [N=522] | 43 | | | |
| Grade 3 Cough; Dose 1 [N=522] | 2 | | | |
| Related Cough; Dose 1 [N=522] | 43 | | | |
| Any Diarrhoea; Dose 1 [N=522] | 18 | | | |
| Grade 3 Diarrhoea; Dose 1 [N=522] | 7 | | | |
| Related Diarrhoea; Dose 1 [N=522] | 17 | | | |
| Any Irritability; Dose 1 [N=522] | 81 | | | |
| Grade 3 Irritability; Dose 1 [N=522] | 4 | | | |
| Related Irritability; Dose 1 [N=522] | 81 | | | |
| Any Loss of appetite; Dose 1 [N=522] | 54 | | | |
| Grade 3 Loss of appetite; Dose 1 [N=522] | 0 | | | |
| Related Loss of appetite; Dose 1 [N=522] | 54 | | | |
| Any Temperature; Dose 1 [N=522] | 94 | | | |
| Grade 3 Temperature; Dose 1 [N=522] | 3 | | | |
| Related Temperature; Dose 1 [N=522] | 94 | | | |
| Any Vomiting; Dose 1 [N=522] | 28 | | | |
| Grade 3 Vomiting; Dose 1 [N=522] | 9 | | | |
| Related Vomiting; Dose 1 [N=522] | 28 | | | |
| Any Cough; Dose 2 [N=501] | 42 | | | |
| Grade 3 Cough; Dose 2 [N=501] | 4 | | | |
| Related Cough; Dose 2 [N=501] | 42 | | | |
| Any Diarrhoea; Dose 2 [N=501] | 9 | | | |
| Grade 3 Diarrhoea; Dose 2 [N=501] | 3 | | | |
| Related Diarrhoea; Dose 2 [N=501] | 9 | | | |
| Any Irritability; Dose 2 [N=501] | 84 | | | |
| Grade 3 Irritability; Dose 2 [N=501] | 2 | | | |
| Related Irritability; Dose 2 [N=501] | 83 | | | |
| Any Loss of appetite; Dose 2 [N=501] | 51 | | | |
| Grade 3 Loss of appetite; Dose 2 [N=501] | 1 | | | |
| Related Loss of appetite; Dose 2 [N=501] | 51 | | | |
| Any Temperature; Dose 2 [N=501] | 101 | | | |
| Grade 3 Temperature; Dose 2 [N=501] | 3 | | | |
| Related Temperature; Dose 2 [N=501] | 101 | | | |
| Any Vomiting; Dose 2 [N=501] | 27 | | | |
| Grade 3 Vomiting; Dose 2 [N=501] | 5 | | | |
| Related Vomiting; Dose 2 [N=501] | 27 | | | |
| Any Cough; Across Doses [N=522] | 71 | | | |
| Grade 3 Cough; Across Doses [N=522] | 6 | | | |

| | | | | |
|--|-----|--|--|--|
| Related Cough; Across Doses [N=522] | 71 | | | |
| Any Diarrhoea; Across Doses [N=522] | 24 | | | |
| Grade 3 Diarrhoea; Across Doses [N=522] | 9 | | | |
| Related Diarrhoea; Across Doses [N=522] | 23 | | | |
| Any Irritability; Across Doses [N=522] | 124 | | | |
| Grade 3 Irritability; Across Doses [N=522] | 6 | | | |
| Related Irritability; Across Doses [N=522] | 123 | | | |
| Any Loss of appetite; Across Doses [N=522] | 83 | | | |
| Grade 3 Loss of appetite; Across Doses [N=522] | 1 | | | |
| Related Loss of appetite; Across Doses [N=522] | 83 | | | |
| Any Temperature; Across Doses [N=522] | 152 | | | |
| Grade Temperature; Across Doses [N=522] | 6 | | | |
| Related Temperature; Across Doses [N=522] | 152 | | | |
| Any Vomiting; Across Doses [N=522] | 45 | | | |
| Grade 3 Vomiting; Across Doses [N=522] | 11 | | | |
| Related Vomiting; Across Doses [N=522] | 45 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting unsolicited adverse events (AEs)

| | |
|-----------------|---|
| End point title | Number of subjects reporting unsolicited adverse events (AEs) |
|-----------------|---|

End point description:

Unsolicited AEs cover any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the 31-day follow-up period after each vaccine dose

| | | | | |
|-----------------------------|-----------------|--|--|--|
| End point values | Rotarix Group | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 522 | | | |
| Units: Subjects | | | | |
| any AE(s) | 25 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting serious adverse events (SAEs)

| | |
|-----------------|--|
| End point title | Number of subjects reporting serious adverse events (SAEs) |
|-----------------|--|

End point description:

SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Throughout the study period (Day 0 to Month 3 or 4)

| End point values | Rotarix Group | | | |
|-----------------------------|-----------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 522 | | | |
| Units: Subjects | | | | |
| any SAE(s) | 1 | | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited general symptoms: during the 8-day (Day 0 - Day7) post-vaccination period. Unsolicited AEs: during the 31-day (Day 0 - Day 30) post-vaccination period and SAEs during the entire period (Day 0 to Month 3 or 4).

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 12.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---------------|
| Reporting group title | Rotarix Group |
|-----------------------|---------------|

Reporting group description:

Subjects received 2 oral doses of Rotarix vaccine at an interval of at least 4 weeks between doses. The first dose was given from the age of 6 weeks and vaccination with both doses was to be completed by 24 weeks of age.

| Serious adverse events | Rotarix Group | | |
|---|-----------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 522 (0.19%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | | | |
| Nervous system disorders | | | |
| Crying | | | |
| subjects affected / exposed | 1 / 522 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 4.6 %

| Non-serious adverse events | Rotarix Group | | |
|---|--------------------|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 247 / 522 (47.32%) | | |
| General disorders and administration site conditions | | | |
| Loss of appetite | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 83 / 522 (15.90%) | | |
| occurrences (all) | 83 | | |
| Irritability | | | |

| | | | |
|--|--------------------|--|--|
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 124 / 522 (23.75%) | | |
| occurrences (all) | 124 | | |
| Fever | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 152 / 522 (29.12%) | | |
| occurrences (all) | 152 | | |
| Vomiting | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 45 / 522 (8.62%) | | |
| occurrences (all) | 45 | | |
| Cough | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 71 / 522 (13.60%) | | |
| occurrences (all) | 71 | | |
| Diarrhoea | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 24 / 522 (4.60%) | | |
| occurrences (all) | 24 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported